Reglan and Tardive Dyskinesia: What the FDA Label Says About Risk

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Specific Medication Risks

If you or someone you care about has taken Reglan (metoclopramide) and developed uncontrollable muscle movements, you may be wondering about the link to tardive dyskinesia. The FDA label for Reglan includes specific warnings about this risk, especially with long-term use. This page provides a clear checklist of the key label points to help you understand the context and what to watch for.

Find Out If You Qualify for Compensation →

Understanding Reglan and Its Link to Tardive Dyskinesia

Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis. However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. For patients in Florida who have developed TD after taking Reglan, understanding the medical and legal landscape is critical, particularly regarding the statute of limitations for filing a claim. Tardive dyskinesia is characterized by involuntary, repetitive movements, often of the face, tongue, or extremities. The condition can be disfiguring and may persist even after the offending medication is discontinued. The clinical presentation of TD includes grimacing, lip smacking, tongue protrusion, and rapid eye blinking, among other movements. Diagnosis is based on a history of exposure to a dopamine-blocking agent, such as metoclopramide, and the presence of characteristic movements after ruling out other causes. Reglan's active ingredient, metoclopramide, works by blocking dopamine receptors in the brain. This mechanism, while effective for gastrointestinal symptoms, can lead to adverse effects in the central nervous system. The U.S. Food and Drug Administration (FDA) has issued a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with the duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the medication should be used for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Mechanism of Action and FDA Warnings

The mechanistic pathway linking Reglan to TD involves chronic dopamine receptor blockade, which can lead to receptor upregulation and supersensitivity. This process may result in an imbalance of neurotransmitters in the basal ganglia, contributing to the involuntary movements seen in TD. The FDA label notes that metoclopramide may also suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect is a critical concern because it can obscure the early symptoms of TD, allowing the condition to progress before it is recognized. Reglan is indicated only for short-term use: 4 to 12 weeks for symptomatic gastroesophageal reflux in adults who fail to respond to conventional therapy, and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA has not shown Reglan to be safe and effective for gastroesophageal reflux beyond 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, the total duration of treatment should not exceed 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, many patients have been prescribed Reglan for extended periods, increasing their risk of developing TD. The adequacy of warnings regarding Reglan and TD is a central issue in legal claims. The FDA boxed warning is clear about the risks, but questions may arise about whether healthcare providers and patients were adequately informed.

Legal Considerations for Florida Patients

For patients who developed TD after prolonged use, the timeline between exposure and documented harm is crucial. TD can emerge months or even years after starting metoclopramide, and symptoms may persist or become permanent after the drug is discontinued. The FDA advises immediate discontinuation of Reglan in patients who develop signs or symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For affected patients in Florida, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Florida, the statute of limitations for personal injury claims is generally four years from the date of injury or from the date the injury was discovered, or should have been discovered, through reasonable diligence. For claims against healthcare providers, the statute of limitations is typically two years. Given the delayed onset of TD, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Reglan caused their condition. Patients should consult with an attorney experienced in pharmaceutical litigation to evaluate their specific circumstances and ensure timely filing. In summary, Reglan use carries a well-documented risk of tardive dyskinesia, a serious and potentially irreversible movement disorder. The FDA has mandated strong warnings, but the risk persists, especially with prolonged use. Patients in Florida who have developed TD after taking Reglan should be aware of the statute of limitations and seek legal advice promptly to protect their rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-related tardive dyskinesia claims in Florida?

In Florida, the statute of limitations for personal injury claims is generally four years from the date of injury or from the date the injury was discovered, or should have been discovered, through reasonable diligence. For claims against healthcare providers, the statute of limitations is typically two years. Given the delayed onset of tardive dyskinesia, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Reglan caused their condition. It is crucial to consult with an attorney promptly to ensure timely filing.

What are the FDA warnings about Reglan and tardive dyskinesia?

The FDA has issued a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk increases with duration of treatment and total cumulative dosage. Reglan is indicated only for short-term use (4 to 12 weeks) and should be discontinued immediately if signs or symptoms of TD develop.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA Boxed Warning for Metoclopramide

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.